Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies

Abstract Background Bradykinin-mediated angioedema (Bk-AE) can be life-threatening and requires specific targeted therapies. Knowledge of its epidemiology may help optimize its management. Methods We systematically searched the medical literature to identify abstracts of interest indexed between 194...

Full description

Bibliographic Details
Main Authors: Emel Aygören-Pürsün, Markus Magerl, Andreas Maetzel, Marcus Maurer
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13023-018-0815-5
id doaj-2b56e802801f4128be2881f03ee055d5
record_format Article
spelling doaj-2b56e802801f4128be2881f03ee055d52020-11-24T22:14:52ZengBMCOrphanet Journal of Rare Diseases1750-11722018-05-011311910.1186/s13023-018-0815-5Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studiesEmel Aygören-Pürsün0Markus Magerl1Andreas Maetzel2Marcus Maurer3Department for Children and Adolescents, University Hospital FrankfurtDepartment of Dermatology and Allergy, Charité – Universitätsmedizin BerlinInstitute of Health Policy, Management & Evaluation, University of TorontoDepartment of Dermatology and Allergy, Charité – Universitätsmedizin BerlinAbstract Background Bradykinin-mediated angioedema (Bk-AE) can be life-threatening and requires specific targeted therapies. Knowledge of its epidemiology may help optimize its management. Methods We systematically searched the medical literature to identify abstracts of interest indexed between 1948 and March, 2016. We used published national survey data on the proportion of the population treated with angiotensin-converting enzyme inhibitors (ACEI) to derive estimates of the population prevalence of ACEI-AE in the USA, Germany and France. For hereditary angioedema (C1-INH-HAE) and C1-inhibitor related acquired angioedema (C1-INH-AAE), publications had to contain original epidemiologic data collection within a defined geographical area. Hereditary angioedema with normal C1-INH was not included in the analysis due to lack of clearly defined criteria. Results We identified 4 relevant publications on the prevalence of ACEI-AE, 6 on the prevalence of C1-INH-HAE, and 1 on the prevalence of C1-INH-AAE. The 1st year cumulative incidence of ACEI-AE was estimated to vary between 0.12 (population-based analyses) and 0.30 (meta-analyses of clinical trials) per 100 patient-years. The population prevalence of ACEI-AE was modeled to vary between 7 and 26 in 100,000. The prevalence of C1-INH-HAE was estimated to vary between 1.1 and 1.6 per 100,000. The prevalence of C1-INH-AAE was estimated to be 0.15 per 100,000 in one epidemiological investigation of AAE in Denmark. Conclusions Epidemiological evidence on Bk-AE is limited to North America and Europe. ACEI-AE is more common than C1-INH-HAE (~ 10:1), which is more common than C1-INH-AAE (~ 10:1). More studies are needed to comprehensively assess the epidemiological burden of Bk-AE.http://link.springer.com/article/10.1186/s13023-018-0815-5AngioedemaBradykininEpidemiologyC1-inhibitorACE-inhibitor
collection DOAJ
language English
format Article
sources DOAJ
author Emel Aygören-Pürsün
Markus Magerl
Andreas Maetzel
Marcus Maurer
spellingShingle Emel Aygören-Pürsün
Markus Magerl
Andreas Maetzel
Marcus Maurer
Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
Orphanet Journal of Rare Diseases
Angioedema
Bradykinin
Epidemiology
C1-inhibitor
ACE-inhibitor
author_facet Emel Aygören-Pürsün
Markus Magerl
Andreas Maetzel
Marcus Maurer
author_sort Emel Aygören-Pürsün
title Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
title_short Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
title_full Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
title_fullStr Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
title_full_unstemmed Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
title_sort epidemiology of bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
publisher BMC
series Orphanet Journal of Rare Diseases
issn 1750-1172
publishDate 2018-05-01
description Abstract Background Bradykinin-mediated angioedema (Bk-AE) can be life-threatening and requires specific targeted therapies. Knowledge of its epidemiology may help optimize its management. Methods We systematically searched the medical literature to identify abstracts of interest indexed between 1948 and March, 2016. We used published national survey data on the proportion of the population treated with angiotensin-converting enzyme inhibitors (ACEI) to derive estimates of the population prevalence of ACEI-AE in the USA, Germany and France. For hereditary angioedema (C1-INH-HAE) and C1-inhibitor related acquired angioedema (C1-INH-AAE), publications had to contain original epidemiologic data collection within a defined geographical area. Hereditary angioedema with normal C1-INH was not included in the analysis due to lack of clearly defined criteria. Results We identified 4 relevant publications on the prevalence of ACEI-AE, 6 on the prevalence of C1-INH-HAE, and 1 on the prevalence of C1-INH-AAE. The 1st year cumulative incidence of ACEI-AE was estimated to vary between 0.12 (population-based analyses) and 0.30 (meta-analyses of clinical trials) per 100 patient-years. The population prevalence of ACEI-AE was modeled to vary between 7 and 26 in 100,000. The prevalence of C1-INH-HAE was estimated to vary between 1.1 and 1.6 per 100,000. The prevalence of C1-INH-AAE was estimated to be 0.15 per 100,000 in one epidemiological investigation of AAE in Denmark. Conclusions Epidemiological evidence on Bk-AE is limited to North America and Europe. ACEI-AE is more common than C1-INH-HAE (~ 10:1), which is more common than C1-INH-AAE (~ 10:1). More studies are needed to comprehensively assess the epidemiological burden of Bk-AE.
topic Angioedema
Bradykinin
Epidemiology
C1-inhibitor
ACE-inhibitor
url http://link.springer.com/article/10.1186/s13023-018-0815-5
work_keys_str_mv AT emelaygorenpursun epidemiologyofbradykininmediatedangioedemaasystematicinvestigationofepidemiologicalstudies
AT markusmagerl epidemiologyofbradykininmediatedangioedemaasystematicinvestigationofepidemiologicalstudies
AT andreasmaetzel epidemiologyofbradykininmediatedangioedemaasystematicinvestigationofepidemiologicalstudies
AT marcusmaurer epidemiologyofbradykininmediatedangioedemaasystematicinvestigationofepidemiologicalstudies
_version_ 1725796681368207360